KILITCH DRUGS Q2 FY27 ; NET PROFIT DOWN 82% AT ₹1 CR (YOY), DOWN 28% (QOQ)

REVENUE UP 3% AT ₹50 CR (YOY), UP 12% (QOQ) EBITDA UP 33% AT ₹7 CR (YOY), UP 128% (QOQ) MARGINS AT 13.3% VS 10.3% (YOY), 6.5% (QOQ)

KILITCH DRUGS INDIA LTD